Fulgent Genetics Inc reports results for the quarter ended in September - Earnings Summary

Fulgent Genetics

03/11/2023 13:32

* Fulgent Genetics Inc  FLGT.OQ  reported a quarterly
adjusted
loss of 39 cents​​ per share for the quarter ended in September,
lower than the same quarter last year, when the company reported
EPS of 32 cents.  The mean expectation of two analysts for the
quarter was for a loss of 33 cents per share. Wall Street
expected results to range from -35 cents to -31 cents per share.
    * Revenue fell 19.8% to $84.69 million from a year ago;
analysts
expected $63.41 million. 
    * Fulgent Genetics Inc's reported EPS for the quarter was a
loss
of 44 cents​.
    * The company reported a quarterly loss of $13.11 million.
    * Fulgent Genetics Inc shares had fallen by 11.0% this
quarter and
lost 20.1% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 4.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the healthcare
facilities & services peer group is  "hold."

Wall Street's median 12-month price target for Fulgent Genetics
Inc is $36.50 
This summary was machine generated from LSEG data November 3 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.33          -0.39          Missed
 Jun. 30 2023      -0.33          -0.08          Beat
 Mar. 31 2023      -0.43          -0.22          Beat
 Dec. 31 2022      -0.56          -0.48          Beat